Skip to main content

Table 2 Adverse Effects

From: Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

 

Placebo N = 116

IR-MPH (tid) N = 102

OROS-MPH N = 67

 
 

N (%)

N (%)

N (%)

Omnibus Statistic

Dry Mouth

5 (4)

22 (22) *

25 (37)*,$

χ2 (2) = 32.2, p < 0.001

Headache

30 (26)

22 (22)

24 (36)

χ2 (2) = 4.2, p = 0.1

Decreased Appetite

4 (3)

11 (11) *

24 (36)*,$

χ2 (2) = 38.8, p < 0.001

GI Complaints

13 (11)

17 (17)

20 (29)*,$

χ2 (2) = 10.3, p = 0.006

Sleep Problems

6 (5)

14 (14) *

14 (21) *

χ2 (2) = 10.5, p = 0.005

Moodiness

7 (6)

15 (15) *

12 (18) *

χ2 (2) = 6.9, p = 0.03

Aches and Pains

13 (11)

7 (7)

9 (13)

χ2 (2) = 2.1, p = 0.3

  1. *, p < 0.05 versus Placebo, $, p < 0.05 versus IR-MPH (tid)
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us